SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

x402jobs

x402jobs ($JOBS) is trending as the community discusses the token's potential, focusing on its revenue-sharing model and current market cap. Technical issues with the chart on some platforms are also being addressed. The community is sharing the contract address for purchase.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to speculation around a potential short squeeze, fueled by its small float and analyst target prices. Community discussions compare it to past runners like $SMX, anticipating a similar explosive move. Traders are closely watching key price levels, particularly the $8 mark, as a breakout point for further upward momentum.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger is trending as discussions around quantum computing's potential impact on crypto security heat up, particularly regarding the vulnerability of major blockchains; the community highlights QRL's unique focus, noting its quantum-resistant design and upcoming Zond upgrade for Ethereum-style smart contracts, positioning it as a hedge against future quantum threats.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders assess its potential as a hedge against market volatility, especially with upcoming economic data releases and geopolitical concerns. The community is actively discussing entry and exit points, while also weighing the impact of contango and reverse splits on its long-term performance. Despite some skepticism about its leverage and decay, UVXY remains a focal point for those seeking to profit from short-term market swings.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as community members discuss potential partnerships and buyout scenarios following positive trial data, with some focusing on the company's unmet medical need in liver cirrhosis. Conversations revolve around speculative buyout prices and the possibility of accelerated FDA approval, with enthusiasm fueled by insider activity and the stock hitting new highs. A recurring theme involves humorous references to "brownies," seemingly tied to the drug's potential benefits.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid discussions about the newly launched Bitwise XRP ETF (TOXR) and potential institutional investment. Community members are debating the impact of ETFs on XRP's price and future, as well as speculating on price movements and potential regulatory developments. Some are drawing comparisons to other cryptocurrencies and discussing technical analysis.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending amid discussions around potential options profitability and general Bitcoin market volatility. Community members are actively debating short-term bearish signals versus long-term bullish prospects, with some pointing to institutional investment and potential regulatory shifts as key factors. The conversation also includes the broader implications of Bitcoin's price movements on related stocks and the overall crypto market.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid discussions about its upcoming earnings report and potential breakout, with some anticipating a significant jump. Community members are weighing in on factors like strong Air Jordan sales and the possible impact of tariff rulings. Some analysts have reiterated buy ratings with high price targets, while others focus on leadership changes and margin pressures.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending amid ongoing buyout speculation and anticipation of upcoming clinical data releases, particularly around CTX112 and CTX211. Community members are actively discussing potential acquisition prices and the likelihood of a deal with Vertex, while also weighing the potential impact of upcoming trial results. Broader discussions include the company's cash position, pipeline potential, and overall sentiment within the gene editing sector.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending as analysts raise price targets, citing strong subscription growth and demand for its AI-native cybersecurity solutions, with Wedbush setting a target of $600. Community members are weighing whether to lock in profits after a significant year-to-date increase or ride the upward momentum, while some express concerns about the stock's valuation. The broader cybersecurity sector is receiving attention amid increasing cyber threats and AI integration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OPKO Health (NASDAQ:OPK) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research note on Saturday...

Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now

OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.

OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of "Hold" by Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are covering the company, Marketbeat Ratings reports. One...

OPKO Health (NASDAQ:OPK) CEO Acquires $771,400.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 580,000 shares of OPKO Health stock in a transaction dated Friday, November 21st. The shares were bought at an...

Zacks Research Boosts Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Research analysts at Zacks Research lifted their FY2025 earnings estimates for OPKO Health in a research report issued on Wednesday, November 19th...

OPKO Health (NASDAQ:OPK) Earns Neutral Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research report on Thursday. They set a "neutral" rating for the company...

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 580,000 Shares

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 580,000 shares of OPKO Health stock in a transaction that occurred on Wednesday, November 19th. The stock was...

Phillip Md Et Al Frost Purchases 533,300 Shares of OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 533,300 shares of the business's stock in a transaction dated Tuesday, November 18th. The stock was acquired at an...

Phillip Md Et Al Frost Acquires 533,300 Shares of OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 533,300 shares of OPKO Health stock in a transaction dated Tuesday, November 18th. The stock was bought at an...

OPKO Health, Inc. $OPK Shares Sold by Y.D. More Investments Ltd

Y.D. More Investments Ltd reduced its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 13.8% in the 2nd quarter, according to the company in its most recent 13F filing with the...

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.07	--	--	N/A
Q3 '25	-$0.06	$0.03	150.51%	BEAT
Q2 '25	-$0.11	-$0.19	-67.65%	MISSED
Q1 '25	-$0.07	-$0.10	-45.83%	MISSED
Q4 '24	-$0.09	$0.01	110.71%	BEAT

OPK
Opko Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest OPK News

OPKOpko Health Inc